Shenzhen Chipscreen Biosciences Co., Ltd.

Total Valuation

Shenzhen Chipscreen Biosciences Co., Ltd. carries a market capitalization of 12.77B, placing it among publicly traded companies globally. Its enterprise value stands at 10.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Shenzhen Chipscreen Biosciences Co., Ltd. currently has 407.80M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 12.71, and the price-to-book ratio stands at 22.01.

Enterprise Valuation

On an enterprise value basis, Shenzhen Chipscreen Biosciences Co., Ltd. trades at an EV/EBITDA multiple of 717.23 and an EV/FCF ratio of 37.54. The EV/Sales ratio of 13.89 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 717.23 provides insight into valuation relative to core operating earnings.

Financial Position

Shenzhen Chipscreen Biosciences Co., Ltd. maintains a current ratio of 1.92, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 90.55, indicating elevated leverage, while an interest coverage ratio of 0.42 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Shenzhen Chipscreen Biosciences Co., Ltd.'s stock has declined approximately -12.13415% over the past 52 weeks. The 50-day moving average sits at 27.93, while the 200-day moving average is 29.83.

Income Statement

Over the trailing twelve months, Shenzhen Chipscreen Biosciences Co., Ltd. generated 762.39M in revenue and converted that into -43.97M in net income, yielding earnings per share of -0.11. EBITDA reached 14.76M, while operating income came in at 14.76M.

Balance Sheet

Shenzhen Chipscreen Biosciences Co., Ltd. holds 567.16M in cash and equivalents against 1.46B in total debt, resulting in a net debt position of 668.87M. Total book value stands at 440.40M, with working capital of 595.89M providing operational flexibility.

Cash Flow

After subtracting -233.14M in capital expenditures, free cash flow totaled -233.14M - equivalent to -0.57 per share.

Margins

Shenzhen Chipscreen Biosciences Co., Ltd. operates with a gross margin of 86.27, reflecting its pricing power and cost economics. The operating margin of 1.94 and net profit margin of -5.77 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -64.01 indicates the proportion of earnings distributed to shareholders.

Scores

Shenzhen Chipscreen Biosciences Co., Ltd. posts an Altman Z-Score of 3.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.